Enoxaparin indications and usage

Enoxaparin
LOVENOX® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Enoxaparin
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]

Indications and Usage

Prophylaxis of Deep Vein Thrombosis

Lovenox® is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE):

in patients undergoing abdominal surgery who are at risk for thromboembolic complications [see Clinical Studies (14.1)]. in patients undergoing hip replacement surgery, during and following hospitalization. in patients undergoing knee replacement surgery. in medical patients who are at risk for thromboembolic complications due to severely restricted mobility during acute illness.

Treatment of Acute Deep Vein Thrombosis

Lovenox is indicated for:

the inpatient treatment of acute deep vein thrombosis with or without pulmonary embolism, when administered in conjunction with warfarin sodium. the outpatient treatment of acute deep vein thrombosis without pulmonary embolism when administered in conjunction with warfarin sodium.

Prophylaxis of Ischemic Complications of Unstable Angina and Non-Q-Wave Myocardial Infarction

Lovenox is indicated for the prophylaxis of ischemic complications of Unstable Angina and non-Q-wave Myocardial Infarction, when concurrently administered with aspirin.

Treatment of Acute ST-Segment Elevation Myocardial Infarction

Lovenox, when administered concurrently with aspirin, has been shown to reduce the rate of the combined endpoint of recurrent Myocardial Infarction or death in patients with acute ST-segment elevation Myocardial Infarction (STEMI) receiving thrombolysis and being managed medically or with PErcutaneous coronary intervention (PCI).